Downregulation of protocadherin-10 expression correlates with malignant behaviour and poor prognosis in human bladder cancer

Journal of International Medical Research

Volumn 41, Issue 1, 2013, Pages 38-47

  Ma, Jian Guo ^a,b   He, Zheng Kai ^a   Ma, Jian Hua ^c   Li, Wen Ping ^b   Sun, Guang ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

^c Chengde Central Hospital   (China)

Author keywords

Bladder cancer; Clinicopathological characteristics; Immunohistochemistry; Protocadherin 10 (PCDH10 )

Indexed keywords

CADHERIN; PROTOCADHERIN 10; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER SURGERY; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA;

EID: 84878413517     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060513476989     Document Type: Article

References (26)

1. Ploeg M, Aben KK and Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol 2009; 27: 289-293.
2. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Jacobs BL, Lee CT and Montie JE. Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010; 60: 244-272.
4. Li Z, Chim JC, Yang M, et al. Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta 2012; 1823: 298-305.
5. Li Y, Yang ZS, Song JJ, et al. Protocadherin-10 is involved in angiogenesis and methylation correlated with multiple myeloma. Int J Mol Med 2012; 29: 704-710.
6. Bertrand KC, Mack SC, Northcott PA, et al. PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Childs Nerv Syst 2011; 27: 1243-1249.
7. Li Z, Li W, Xie J, et al. Epigenetic inactivation of PCDH10 in human prostate cancer cell lines. Cell Biol Int 2011; 35: 671-676.
8. Li Z, Xie J, Li W, et al. Identification and characterization of human PCDH10 gene promoter. Gene 2011; 475: 49-56.
9. Yu B, Yang H, Zhang C, et al. Highresolution melting analysis of PCDH10 methylation levels in gastric, colorectal and pancreatic cancers. Neoplasma 2010; 57: 247-252.
10. Wang KH, Liu HW, Lin SR, et al. Field methylation silencing of the protocadherin 10 gene in cervical carcinogenesis as a potential specific diagnostic test from cervical scrapings. Cancer Sci 2009; 100: 2175-2180.
11. Ying J, Li H, Seng TJ, et al. Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene 2006; 25: 1070-1080.
12. Oosterlinck W, Lobel B, Jakse G, et al. Guidelines on bladder cancer. Eur Urol 2002; 41: 105-112.
13. Lin YL, Liu XQ, Li WP, et al. Promoter methylation of H-cadherin is a potential biomarker in patients with bladder transitional cell carcinoma. Int Urol Nephrol 2012; 44: 111-117.
14. Lin YL, Sun G, Liu XQ, et al. Clinical significance of CDH13 promoter methylation in serum samples from patients with bladder transitional cell carcinoma. J Int Med Res 2011; 39: 179-186.
15. Puri KS, Suresh KR, Gogtay NJ, et al. Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med 2009; 55: 131-134.
16. Lin Y, Sun G, Liu X, et al. Clinical significance of T-cadherin tissue expression in patients with bladder transitional cell carcinoma. Urol Int 2011; 86: 340-345.
17. Zhang CT, Lu R, Lin YL, et al. The significance of fragile histidine triad protein as a molecular prognostic marker of bladder urothelial carcinoma. J Int Med Res 2012; 40: 507-516.
18. Koksal IT, Ates M, Danisman A, et al. Reduced E-cadherin and α-catenin expressions have no prognostic role in bladder carcinoma. Pathol Oncol Res 2006; 12: 13-19.
19. Black PC and Dinney CP. Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 2007; 26: 623-634.
20. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-2422.
21. Morgan TM, Keegan KA and Clark PE. Bladder cancer. Curr Opin Oncol 2011; 23: 275-282.
22. Yu J, Cheng YY, Tao Q, et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009; 136: 640-651.
23. Patel T, Pitman M and McKiernan JM. Bladder cancer: a review of clinical management and prognostic factors. Minerva Urol Nefrol 2010; 62: 377-386.
24. Jancke G, Rosell J and Chebil G. Bladder wash cytology at diagnosis of Ta-T1 bladder cancer is predictive for recurrence and progression. Urology 2012; 80: 625-631.
25. Ku JH and Lerner SP. Strategies to prevent progression of high-risk bladder cancer at initial diagnosis. Curr Opin Urol 2012; 22: 405-414.
26. Rodríguez Faba O and Palou J. Predictive factors for recurrence progression and cancer specific survival in high-risk bladder cancer. Curr Opin Urol 2012; 22: 415-420.